Atezolizumab in metastatic urothelial carcinoma outside clinical trials: focus on efficacy, safety, and response to subsequent therapies

PC Barata, D Gopalakrishnan, VS Koshkin… - Targeted Oncology, 2018 - Springer
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …
被引用次数：16 相关文章

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

PC Barata, D Gopalakrishnan, VS Koshkin… - Targeted …, 2018 - search.proquest.com
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

PC Barata, D Gopalakrishnan… - Targeted …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …

[引用][C] Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

PC Barata, D Gopalakrishnan, VS Koshkin… - Targeted …, 2018 - cir.nii.ac.jp
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy,
Safety, and Response to Subsequent Therapies | CiNii Research CiNii 国立情報学研究所 学術 …

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

PC Barata, D Gopalakrishnan, VS Koshkin… - Targeted Oncology, 2018 - infona.pl
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …